Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting

• Published in: Journal of advanced pharmaceutical technology and research Vol. 3; no. 4; pp. 202 - 9
• Main Author: Prasan R Bhandari
• Format: Journal Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 01.01.2012
• ISSN: 2231-4040; 0976-2094
• DOI: 10.4103/2231-4040.107376

Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients. Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV). During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV, and resulted in more effective and better tolerated treatment of CINV. Despite recent progress, however, a significant number of patients still develop CINV, particularly during the 2-5-day period (delayed emesis) following chemotherapy. There is evidence that this may be an underappreciated problem on the part of some caregivers. Recently, two new antiemetics, aprepitant, the first member of the neurokinin-1 antagonists, and palonosetron, a second-generation 5-hydroxytryptamine receptor antagonist, received regulatory approval in the U.S. Both represent useful additions to the therapeutic armamentarium for the management of CINV.